A Cochrane review [Abstract] 1 included 8 studies. The protective effect within the first year of vaccination was consistent across the trials. The summary vaccine efficacy was 95% (95% CI 87% to 99%). Protection extended into the second and third year after vaccination but the results did not attain statistical significance. The vaccine was protective in Finnish children aged 3 months to five years. The latter was also the only trial that assessed the effect of a booster dose in children under two years of age but lacked power to yield statistically significant results. The vaccine was protective in one- to five-year old children in developing countries (Nigeria and Sudan) but the age-specific efficacy in strata between one and five years of age could not be determined.
Primary/Secondary Keywords